Lipid Metabolism, Cardiovascular Diseases
Conditions
Brief summary
Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL) cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor could bring metabolic change in serum, in order to investigate the metabolic modification, we conduct this clinical trial.
Interventions
DRUGPCSK9 inhibitor
For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
Sponsors
Shenzhen People's Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* New diagnosis ACS patient by serum biomarker and coronary arteriography.
Exclusion criteria
* Severe renal dysfunction acute or chronic bacterial and viral infections sleep apnea cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cardiovascular prognosis | 52 weeks | composite outcome of time to first occurrence of cardiovascular death, myocardial infarction, unstable angina and heart failure. |
Countries
China
Contacts
Primary ContactTangzhiming Li, PhD.
Backup ContactShaohong Dong, PhD.
Outcome results
None listed